Central Nervous System Origin Vertigo disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CNT017 MIFTS: 43	Central Nervous System Origin Vertigo Categories: Ear diseases, Neuronal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Central Nervous System Origin Vertigo

MalaCards integrated aliases for Central Nervous System Origin Vertigo:

Name: Central Nervous System Origin Vertigo ¹¹ ¹⁴ ⁷¹

Vertigo of Central Origin ¹¹ ³¹

Vertigo ⁴³ ⁷⁵

Central Vestibular Vertigo ¹¹

Classifications:

MalaCards categories:
Anatomical: Ear diseases Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Diseases of the ear and mastoid process

Diseases of inner ear

Disorders of vestibular function

Vertigo of central origin

External Ids:

Disease Ontology ¹¹ DOID:2479

ICD9CM ³⁴ 386.2

MeSH ⁴³ D014717

SNOMED-CT ⁶⁸ 20425006

ICD10 ³¹ H81.4

UMLS ⁷¹ C0155503

Sources

Summaries for Central Nervous System Origin Vertigo

Disease Ontology: ¹¹ A brain disease that is characterized by vertigo caused by hemorrhagic insult, ischemic insult or mass lesion of the cerebellum, the vestibular nuclei, and the brainstem, has symptom dizziness, has symptom nausea, has symptom vomiting and has symptom difficulty walking.

MalaCards based summary: Central Nervous System Origin Vertigo, also known as vertigo of central origin, is related to sneddon syndrome and cerebrovascular disease, and has symptoms including vomiting, difficulty walking and nausea. An important gene associated with Central Nervous System Origin Vertigo is CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A), and among its related pathways/superpathways are Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) and Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs). The drugs Dopamine and Calcium carbonate have been mentioned in the context of this disorder. Affiliated tissues include cerebellum, brain and liver, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: ⁷⁵ Vertigo is a condition where a person has the sensation of movement or of surrounding objects moving... more...

Sources

Related Diseases for Central Nervous System Origin Vertigo

Diseases related to Central Nervous System Origin Vertigo via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 873)

#	Related Disease	Score	Top Affiliating Genes
1	sneddon syndrome	31.3	SERPINC1 F2
2	cerebrovascular disease	30.4	PLG MTHFR F2
3	migraine with aura	30.3	MTHFR F2 CACNA1A
4	migraine with or without aura 1	30.3	POLG PLG MTHFR F2 CACNA1A ATP4A
5	facial paralysis	30.1	PLG ACE2
6	migraine without aura	30.1	MTHFR CACNA1A
7	cranial nerve palsy	30.0	SERPINC1 F2
8	transient cerebral ischemia	29.9	SERPINC1 PLG MTHFR F2
9	abducens palsy	29.9	SERPINC1 F2
10	ocular motility disease	29.8	POLG CACNA1A
11	apnea, obstructive sleep	29.8	ATP4A ATP12A
12	vitamin b12 deficiency	29.7	MTHFR ATP4A ATP12A
13	somatoform disorder	29.7	ATP4A ATP12A
14	mastoiditis	29.6	SERPINC1 MTHFR F2
15	stroke, ischemic	29.6	SERPINC1 PLG MTHFR F2 ACE2
16	cavernous hemangioma	29.5	SERPINC1 F2
17	behcet syndrome	29.5	SERPINC1 MTHFR F2
18	pernicious anemia	29.5	ATP4A ATP12A
19	chickenpox	29.4	F2 ACE2
20	intracranial hypotension	29.4	SERPINC1 MTHFR F2
21	thrombophilia due to thrombin defect	29.4	SERPINC1 MTHFR F2
22	eclampsia	29.4	SERPINC1 MTHFR F2
23	dysentery	29.4	ATP4A ATP12A
24	antiphospholipid syndrome	29.4	SERPINC1 MTHFR F2
25	covid-19	29.3	PLG F2 ACE2
26	viral pneumonia	29.2	F2 ACE2
27	urinary tract infection	29.2	F2 ATP4A ATP12A
28	nutritional deficiency disease	29.2	MTHFR F2 ATP4A ATP12A
29	cerebral palsy	29.1	SERPINC1 MTHFR F2 CACNA1A
30	thrombophilia due to activated protein c resistance	28.9	SERPINC1 PLG MTHFR F2
31	budd-chiari syndrome	28.9	SERPINC1 PLG MTHFR F2
32	peripheral vascular disease	28.9	SERPINC1 PLG MTHFR F2
33	atrial heart septal defect	28.9	SERPINC1 PLG MTHFR F2
34	cardiovascular system disease	28.9	SERPINC1 PLG MTHFR ACE2
35	respiratory failure	28.6	SERPINC1 PLG F2 ACE2
36	deficiency anemia	28.5	SERPINC1 PLG F2 ATP4A ATP12A
37	myocardial infarction	28.3	SERPINC1 PLG MTHFR F2 ACE2
38	patent foramen ovale	28.1	SERPINC1 PLG MTHFR F2 CACNA1A ACE2
39	hypertension, essential	28.0	SERPINC1 PLG MTHFR F2 ATP4A ATP12A
40	nervous system disease	27.6	SERPINC1 POLG PLG MTHFR F2 CACNA1A
41	meniere disease	11.7
42	episodic ataxia, type 3	11.3
43	viral labyrinthitis	11.3
44	peripheral vertigo	11.3
45	vertigo, benign recurrent, 2	11.2
46	herpes zoster oticus	11.2
47	vestibular disease	11.1
48	vestibular neuronitis	11.1
49	acoustic neuroma	11.1
50	superior semicircular canal dehiscence	11.1

Comorbidity relations with Central Nervous System Origin Vertigo via Phenotypic Disease Network (PDN):

Hypertension, Essential

Graphical network of the top 20 diseases related to Central Nervous System Origin Vertigo:

Sources

Symptoms & Phenotypes for Central Nervous System Origin Vertigo

Symptoms:

¹¹

• vomiting
• difficulty walking

• nausea
• dizziness

UMLS symptoms related to Central Nervous System Origin Vertigo:

vertigo

MGI Mouse Phenotypes related to Central Nervous System Origin Vertigo:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	9.97	ACE2 ATP12A ATP4A CACNA1A F2 MTHFR
2	growth/size/body region	MP:0005378	9.91	ACE2 ATP12A ATP4A CACNA1A F2 MTHFR
3	digestive/alimentary	MP:0005381	9.63	ACE2 ATP12A ATP4A F2 PLG POLG
4	mortality/aging	MP:0010768	9.56	ACE2 ATP4A CACNA1A F2 MTHFR PLG
5	integument	MP:0010771	9.1	ACE2 CACNA1A F2 MTHFR PLG POLG

Sources

Drugs & Therapeutics for Central Nervous System Origin Vertigo

Drugs for Central Nervous System Origin Vertigo (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 152)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Dimenhydrinate

Approved

Phase 4

523-87-5

10660

Piracetam

Approved, Investigational

Phase 4

7491-74-9

4843

Phenol

Approved, Experimental

Phase 4

108-95-2

996

Ethanol

Approved

Phase 4

64-17-5

702

Glycerin

Approved, Investigational

Phase 4

56-81-5

753

Thymol

Approved

Phase 4

89-83-8

6989

Caffeine

Approved

Phase 4

58-08-2

2519

Nicotinamide

Approved, Investigational

Phase 4

98-92-0

936

Diphenidol

Approved, Investigational, Withdrawn

Phase 4

972-02-1

3055

Tocopherol

Approved, Investigational

Phase 4

1406-66-2

Mecobalamin

Approved, Investigational

Phase 4

13422-55-4

Ginger

Approved

Phase 4

Hydroxocobalamin

Approved

Phase 4

13422-51-0

15589840 44475014

gamma-Aminobutyric acid

Approved, Investigational

Phase 4

56-12-2

119

Montelukast

Approved

Phase 4

158966-92-8

5281040

DL-alpha-Tocopherol

Approved, Experimental, Investigational, Nutraceutical, Vet_approved

Phase 4

59-02-9, 10191-41-0

2116 14985

Niacin

Approved, Investigational, Nutraceutical

Phase 4

59-67-6

938

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Pyridoxine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

65-23-6

1054

Cyanocobalamin

Approved, Nutraceutical

Phase 4

68-19-9

24892734 16212801 44176380

Glutamic acid

Approved, Nutraceutical

Phase 4

56-86-0

33032

Thiamine

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

70-16-6

1130

Tocotrienol

Investigational

Phase 4

6829-55-6

9929901

Cobalamin

Experimental

Phase 4

13408-78-1

6857388

Dopamine Agents

Phase 4

Anti-Ulcer Agents

Phase 4

Antacids

Phase 4

Calcium Supplement

Phase 4

Antiemetics

Phase 4

Histamine phosphate

Phase 4

51-74-1

134614

Histamine H1 Antagonists

Phase 4

Histamine Antagonists

Phase 4

Vasodilator Agents

Phase 4

Dopamine Antagonists

Phase 4

Pharmaceutical Solutions

Phase 4

Neuroprotective Agents

Phase 4

Nootropic Agents

Phase 4

Protective Agents

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Antioxidants

Phase 4

Central Nervous System Stimulants

Phase 4

Vitamin B3

Phase 4

Nicotinic Acids

Phase 4

Antimetabolites

Phase 4

Hypolipidemic Agents

Phase 4

Lipid Regulating Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 189)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging	Unknown status	NCT00132223	Phase 4	Contrast agent
2	Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in Benign Paroxysmal Positional Vertigo: A Prospective Multicenter Randomized Trial	Completed	NCT02031692	Phase 4	400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
3	Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial	Completed	NCT01890538	Phase 4	Administration of 100 mg dimenhydrinate intravenous;2 g piracetam intravenous
4	Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo	Completed	NCT02253524	Phase 4	Dimenhydrinate;Metoclopramide
5	Randomized, Placebo-Controlled Evaluation of Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal	Completed	NCT00765635	Phase 4	drops intilation (Taponoto ® );drops intilation (Otocerum®);drops intilation (Placebo)
6	Effect of Caffeine Intake in Vestibular Function: A Randomized Triple-Blind Controlled Trial	Completed	NCT02825199	Phase 4
7	Effect of Stellate Ganglion Block on Meniere's Disease	Completed	NCT01574313	Phase 4	0.25mg, fludiazine;25mg [email protected] (diphenidol);200mg [email protected] (tocopherol nicotinate).
8	Double Blind Evaluation of Gamma-aminobutyric Acid Tartarate 100 mg, Glutamic Acid 100 mg, Dibasic Calcium Phosphate 50 mg, Thiamine Nitrate 25 mg, Pyridoxine Chloride 10 mg and Cyanocobalamin 5 mcg Versus Ginger for Vertigo-kinetosis	Recruiting	NCT05221892	Phase 4	Gamma-aminobutyric acid tartarate, glutamic acid, dibasic calcium phosphate, thiamine nitrate, pyridoxine chloride and cyanocobalamin;Ginger
9	Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease	Recruiting	NCT04815187	Phase 4	Montelukast;Placebo
10	A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation	Withdrawn	NCT00474409	Phase 4	Merislon
11	" National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin"	Unknown status	NCT02112578	Phase 3	Meclizine;Dimenhydrinate
12	Assessment of Acyclovir Efficacy Versus Placebo in Controlling Vertigo Attacks of Patients With Meniere's Disease Visited in Amiralam Hospital	Unknown status	NCT01729767	Phase 2, Phase 3	Acyclovir;Placebo
13	Randomized Multicenter Study of Treatment of Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT00810641	Phase 3
14	The Effectiveness Comparison of Three Different Methods for the Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo: Prospective, Double Blinded, Randomized, Multicenter Clinical Trial	Completed	NCT02029508	Phase 3
15	Treatment of Benign Paroxysmal Positional Vertigo With the Canalith Repositioning Procedure in Family Practice: A Randomized Controlled Trial	Completed	NCT00182273	Phase 3
16	Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo; Randomized Controlled Trial of Barbeque Rotation and Gufoni Maneuver	Completed	NCT01366430	Phase 3
17	Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg (JSC Valenta Pharm, Russia) in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo	Completed	NCT05430217	Phase 3	Buspirone;Placebo
18	Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial	Completed	NCT01827293	Phase 3	Promethazine;Lorazepam
19	A Phase II/III Trial on Rizatriptan for Vestibular Migraine	Completed	NCT02447991	Phase 2, Phase 3	Rizatriptan;Placebo
20	Comparison of Efficacy of Metoclopramide , Promethazine and Prochloroperazine in the Treatment of Vertigo.	Recruiting	NCT05586763	Phase 3	Metoclopramid ( 10mg), IM promethazine (25mg) , IM prochloroperazine( 12.5mg)
21	Visual Feedback Goggle For The Treatment Of Benign Paroxysmal Positional Vertigo in a Randomized Single-Blind Study	Unknown status	NCT00729885	Phase 1, Phase 2
22	A Double Blinded Randomized Control Trial (RCT) to Evaluate the Effectiveness of Vitamin D Treatment in Lowering the Recurrence Rate of Benign Paroxysmal Positional Vertigo (BPPV) in Older Patients	Unknown status	NCT04578470	Phase 2	Vitamin D;Placebo
23	Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study	Completed	NCT02158585	Phase 2	Lamotrigine;Placebo
24	Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo	Completed	NCT02046980	Phase 2
25	Treatments for Benign Paroxysmal Positional Vertigo (BPPV)	Completed	NCT00000359	Phase 2
26	Comparison of Treatment Efficacy of Automated Robotic Maneuvering System (RMS) Reposition Chair Versus Traditional Manual Repositioning Maneuvers in Benign Paroxysmal Positional Vertigo (BPPV)	Completed	NCT05352555	Phase 1, Phase 2
27	Multicenter Randomized Controlled Phase 2 Trial to Evaluate AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS)	Completed	NCT03908567	Phase 2	Intranasal Drug;Oral Tablet
28	A Multicenter, Double-Blind, Phase Ⅱ Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction	Completed	NCT02299804	Phase 2	Levophencynonate Hydrochloric;Placebo
29	Effect of V0251 in Acute Vertigo	Completed	NCT01583738	Phase 2	V0251;placebo
30	A Randomized, Prospective, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Effectiveness of a Combination of Lamotrigine and Bupropion to Treat Meniere's Disease	Recruiting	NCT05420350	Phase 2	Lamotrigine and Bupropion;Placebo
31	Effect of Jaeumgeonbi-Tang on Chronic Subjective Dizziness: A Randomized, Double-Blind, Parallel-group, Placebo-Controlled Trial	Suspended	NCT05482828	Phase 2	JGT (Jaeumgeonbi-Tang) tablet;Placebo tablet
32	Efficacy of Extended-release, Once Daily Tramadol for Post Operative in Ambulatory Shoulder Arthroscopy	Terminated	NCT02247648	Phase 2	tramadol;Placebo
33	Pharmacologic Dissection of Vestibular Migraine and Chronic Subjective Dizziness: A Double-Blind Parallel Group Trial Comparing Response to Verapamil Versus Sertraline	Completed	NCT01669304	Phase 1	Verapamil;Sertraline
34	Multicentre, Open Label, Phase I Clinical Trial to Evaluate the Safety of APSLXR for the Treatment of Vertigo of Vestibular Origin or Meniere's Disease	Withdrawn	NCT04674735	Phase 1	APSLXR
35	Do Migrainous Vertigo Patients Have More Hypersensitivity in Their Vestibular System Than Migraine Patients Without Vertigo?	Unknown status	NCT00901953
36	Comparison of the Treatment Outcomes of Posterior Canal Benign Paroxysmal Positional Vertigo (BPPV) With Canalith Repositioning Procedure (CRP): Single Versus Multiple Cycles	Unknown status	NCT02701218
37	Epley Manoeuvre for Posterior Semi-circular Canal Benign Paroxysmal Positional Vertigo in People With Multiple Sclerosis: Protocol of a Randomized Controlled Trial	Unknown status	NCT04578262
38	Efficacy of Postural Restriction in Treating Benign Paroxysmal Positional Vertigo	Unknown status	NCT02475239
39	Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Dizziness Trial	Unknown status	NCT04026516
40	Randomized Controlled Trials for Treatment of Benign Paroxysmal Positional Vertigo	Unknown status	NCT01822002
41	Vestibular Function Evaluated by the Video Head Impulse Test (vHIT) and Vertigo Perceived by the Patients Before and After Cochlear Implant Surgery.	Unknown status	NCT02584361
42	The Use of Virtual Reality for the Treatment of Visual Vertigo.	Unknown status	NCT03020654
43	The Effect of Vestibular Exercise, With or Without Medication, in Managing Residual Dizziness After Successful Repositioning Maneuvers in Patients With Benign Paroxysmal Positional Vertigo	Unknown status	NCT03624283		Betahistine
44	Saccular Dilatation, Endolymphatic Hydrops and Vestibular Schwannoma : is Vertigo Really Correlated to the Tumor ? A Retrospective Study Based on FIESTA-C Sequence Using a 3 Tesla MRI	Unknown status	NCT03593577
45	Tailored Care for Somatoform Vertigo/Dizziness - From Diagnostics to Therapy	Unknown status	NCT02320851
46	Therapeutic Effects and Safety of Percutaneous Disc Decompression With Coblation Nucleoplasty in Cervical Vertigo	Unknown status	NCT03485768
47	Inactivity, Balance Problems and Fall Risk in Institutionalized Frail Elderly: What is the Impact of Benign Paroxysmal Positional Vertigo (BPPV) and Treatment Effectiveness?	Unknown status	NCT02905292
48	Vestibular Function and Vestibular Rehabilitation in Sudden Sensorneural Hearing Loss With Vertigo	Unknown status	NCT03431506
49	Semicircular Canals Dysfunction Among Patients Hospitalized at the Rehabilitation Department	Unknown status	NCT04447066
50	DeepDoc - Clinical Validation of an AI-based Decision Support System in the Early Diagnostic Evaluation of Neurological Diseases: a Prospective Multi-center Study	Unknown status	NCT04055766

Search NIH Clinical Center for Central Nervous System Origin Vertigo

Cochrane evidence based reviews: vertigo

Sources

Genetic Tests for Central Nervous System Origin Vertigo

Sources

Anatomical Context for Central Nervous System Origin Vertigo

Organs/tissues related to Central Nervous System Origin Vertigo:

MalaCards : Cerebellum, Brain, Liver, Eye

Sources

Publications for Central Nervous System Origin Vertigo

Articles related to Central Nervous System Origin Vertigo:

(show all 32)

#	Title	Authors	PMID	Year
1	Vestibular disorders in patients after COVID-19 infection. ⁶²	Pazdro-Zastawny K...Zatonski T	36203969	2022
2	[Stabilometric diagnosis of vertigo in elderly patients with vestibular migraine.] ⁶²	Illarionova EM...Golovanova ED	34998017	2021
3	A Rare Case of a Large, Deceitfully Quiet Brainstem Arteriovenous Malformation Presenting Only as Dizziness. ⁶²	Rao S...Giron F	32754407	2020
4	Economic burden of vertigo: a systematic review. ⁶²	Kovacs E...Grill E	31883042	2019
5	Description of a new type of benign recurrent vertigo of central origin. ⁶²	Bisdorff A...Kattah J	29792304	2018
6	Vestibular evoked myogenic potentials and video head impulse test in patients with vertigo, dizziness and imbalance. ⁶²	Skoric MK...Habek M	28242131	2017
7	[Benign paroxysmal positional vertigo]. ⁶²	Kutlubaev MA	27070476	2016
8	[Vestibular neuritis: treatment and prognosis]. ⁶²	Reinhard A...Maire R	24187751	2013
9	Infratentorial hygroma secondary to decompressive craniectomy after cerebellar infarction. ⁶²	Tejada-Solis S...Gomez-Ibanez A	19830371	2009
10	[Causes and diagnostics of dizziness of central origin in children]. ⁶²	Gergont A...Steczkowska M	20297643	2009
11	Central vestibular disorders. ⁶²	Dieterich M	17417688	2007
12	Clinical investigation on hypotensive patients with vertigo. ⁶²	Yang CS...Young YH	16816934	2006
13	[Results of transcranial Doppler examination of cerebral blood flow in children with vertigo]. ⁶²	Gergont A...Nowak A	17348419	2006
14	[Additive treatment for central vestibular vertigo]. ⁶²	Sauer H	15459763	2004
15	Differentiation between cerebellopontine angle tumors in cancer patients. ⁶²	Huang TW...Young YH	12438865	2002
16	Intravenous Lorazepam versus dimenhydrinate for treatment of vertigo in the emergency department: a randomized clinical trial. ⁶²	Marill KA...Nelson BK	11020677	2000
17	[Vertigo of central origin in a hypertensive patient]. ⁶²	Lozares Sanchez A...Rosillo Gonzalez A	10730449	2000
18	The effectiveness of piracetam in vertigo. ⁶²	Oosterveld WJ	10338110	1999
19	Prochlorperazine versus cinnarizine in cases of vertigo. ⁶²	Singh AK...Chaturvedi VN	23119469	1998
20	Smooth pursuit neck torsion test: a specific test for cervical dizziness. ⁶²	Tjell C...Rosenhall U	9455954	1998
21	Approach to the dizzy patient. ⁶²	Baloh RW	7874402	1994
22	Dyscalculia in patients with vertigo. ⁶²	Risey J...Briner W	1670135	1990
23	Sudden vertigo of central origin. ⁶²	Mangabeira-Albernaz PL...Gananca MM	3261109	1988
24	Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. ⁶²	Holmes B...Avery GS	6141044	1984
25	[Phenomenology and differential diagnosis of peripheral and central vestibular vertigo]. ⁶²	Bohnert B	7019143	1981
26	Velocity of rapid eye movements and vertigo of central origin. ⁶²	Pyykko I...Schalen L	7224516	1981
27	The efficacy of piracetam in vertigo. A double-blind study in patients with vertigo of central origin. ⁶²	Oosterveld WJ	7006617	1980
28	[Vertigo of central origin]. ⁶²	Labauge R...Rouy JM	4411493	1974
29	Vertigo of Central Origin. ⁶²		19994159	1962
30	Vertigo of central origin. ⁶²	McGOVERN FH	13648026	1959
31	[Vertigo of central origin]. ⁶²	AUBRY M...PIALOUX P	14396083	1955
32	Case of Vertigo of Central Origin. ⁶²	Lake R	19983920	1924

Sources

Genes for Central Nervous System Origin Vertigo

Genes related to Central Nervous System Origin Vertigo (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CACNA1A	Calcium Voltage-Gated Channel Subunit Alpha1 A	Protein Coding	5.47	DISEASES inferred ¹⁴
2	POLG	DNA Polymerase Gamma, Catalytic Subunit	Protein Coding	4.35	DISEASES inferred ¹⁴
3	MTHFR	Methylenetetrahydrofolate Reductase	Protein Coding	3.57	DISEASES inferred ¹⁴
4	SERPINC1	Serpin Family C Member 1	Protein Coding	3.34	DISEASES inferred ¹⁴
5	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	3.09	DISEASES inferred ¹⁴
6	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	3.09	DISEASES inferred ¹⁴
7	PLG	Plasminogen	Protein Coding	3.03	DISEASES inferred ¹⁴
8	ACE2	Angiotensin Converting Enzyme 2	Protein Coding	2.98	DISEASES inferred ¹⁴
9	F2	Coagulation Factor II, Thrombin	Protein Coding	2.92	DISEASES inferred ¹⁴

Sources

Variations for Central Nervous System Origin Vertigo

Sources

Expression for Central Nervous System Origin Vertigo

Search GEO for disease gene expression data for Central Nervous System Origin Vertigo.

Sources

Pathways for Central Nervous System Origin Vertigo

Pathways related to Central Nervous System Origin Vertigo according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) ⁶⁶ Show member pathways Blood clotting cascade ⁷⁴ Blood Coagulation Signaling Pathways ⁶⁵ Common Pathway of Fibrin Clot Formation ⁶⁶ Complement and coagulation cascades ⁷⁴ Defective F8 binding to von Willebrand factor ⁶⁶ Defective F8 cleavage by thrombin ⁶⁶ Defective F8 sulfation at Y1699 ⁶⁶ Defective F9 activation ⁶⁶ Defective F9 secretion ⁶⁶ Defective factor IX causes hemophilia B ⁶⁶ Defective factor VIII causes hemophilia A ⁶⁶ Defective factor XII causes hereditary angioedema ⁶⁶ Defective gamma-carboxylation of F9 ⁶⁶ Diseases of hemostasis ⁶⁶ Extrinsic Pathway of Fibrin Clot Formation ⁶⁶ Extrinsic Prothrombin Activation Pathway ⁶⁴ Formation of Fibrin Clot (Clotting Cascade) ⁶⁶ Intrinsic Pathway of Fibrin Clot Formation ⁶⁶ Thrombin/protease-activated receptor (PAR) pathway ⁶¹	11.96	SERPINC1 PLG F2
2	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶ Show member pathways Post-translational protein phosphorylation ⁶⁶	11.8	SERPINC1 PLG F2
3	Syndecan-4-mediated signaling events ⁶¹	10.65	PLG F2
4	A-beta Plaque Formation and APP Metabolism ⁶⁵	10.32	PLG ACE2
5	COVID-19, thrombosis and anticoagulation ⁷⁴	9.47	PLG F2

Sources

GO Terms for Central Nervous System Origin Vertigo

Cellular components related to Central Nervous System Origin Vertigo according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	blood microparticle	GO:0072562	9.1	SERPINC1 PLG F2

Biological processes related to Central Nervous System Origin Vertigo according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cellular sodium ion homeostasis	GO:0006883	9.76	ATP4A ATP12A
2	fibrinolysis	GO:0042730	9.73	PLG F2
3	sodium ion export across plasma membrane	GO:0036376	9.71	ATP4A ATP12A
4	cellular potassium ion homeostasis	GO:0030007	9.67	ATP4A ATP12A
5	negative regulation of fibrinolysis	GO:0051918	9.62	PLG F2
6	establishment or maintenance of transmembrane electrochemical gradient	GO:0010248	9.46	ATP4A ATP12A
7	regulation of blood coagulation	GO:0030193	9.43	SERPINC1 F2
8	blood coagulation	GO:0007596	9.43	SERPINC1 PLG F2
9	hemostasis	GO:0007599	8.8	SERPINC1 PLG F2

Molecular functions related to Central Nervous System Origin Vertigo according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ATPase-coupled monoatomic cation transmembrane transporter activity	GO:0019829	9.56	ATP4A ATP12A
2	P-type sodium:potassium-exchanging transporter activity	GO:0005391	9.46	ATP4A ATP12A
3	P-type potassium transmembrane transporter activity	GO:0008556	8.96	ATP4A ATP12A
4	P-type potassium:proton transporter activity	GO:0008900	8.92	ATP4A ATP12A